MedTrace Logo

Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients

NCT02106962 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2017-09-25

Study results available
· View outcomes & findings →

Summary

This study will investigate how the use of Tranexamic acid and Bacitracin applied to the bleeding site after the hemodialysis fistula needle is removed will affect Time to Clot and Infection Rate

Conditions

  • Arteriovenous Fistula

Interventions

DRUG

Topical Tranexamic Acid 5% with bacitracin

Selected participants received a fixed amount of tranexamic acid 5 %and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.

OTHER

Topical Tranexamic Acid 25% with bacitracin

Selected participants received a fixed amount of tranexamic acid 25%and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.

Sponsors & Collaborators

  • Imprimis Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • California Institute of Renal Research

    lead OTHER

Principal Investigators

  • Mark Boiskin, MD · California Institute of Renal Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02106962 on ClinicalTrials.gov